Activin and Inhibin

DLK-IN-1 is a selective, orally active inhibitor of dual leucine zipper kinase (DLK, MAP3K12) , with a K i of 3 nM. DLK-IN-1 retains excellent CNS penetration and is well tolerated following multiple days of dosing at concentrations that exceed

DLK-IN-1 is a selective, orally active inhibitor of dual leucine zipper kinase (DLK, MAP3K12) , with a K i of 3 nM. DLK-IN-1 retains excellent CNS penetration and is well tolerated following multiple days of dosing at concentrations that exceed

DMAPT (Dimethylamino Parthenolide), an analogue of Parthenolide (PTL), is an oral active NF-κB inhibitor, with a LD 50 of 1.7 μM for cell population in AML cells. Has potential anti-cancer and anti-metastatic effectIn VitroDMAPT treatment decreased

DMAPT (Dimethylamino Parthenolide), an analogue of Parthenolide (PTL), is an oral active NF-κB inhibitor, with a LD 50 of 1.7 μM for cell population in AML cells. Has potential anti-cancer and anti-metastatic effectIn VitroDMAPT treatment decreased

DMAPT (Dimethylamino Parthenolide), an analogue of Parthenolide (PTL), is an oral active NF-κB inhibitor, with a LD 50 of 1.7 μM for cell population in AML cells. Has potential anti-cancer and anti-metastatic effectIn VitroDMAPT treatment decreased

DMAPT (Dimethylamino Parthenolide), an analogue of Parthenolide (PTL), is an oral active NF-κB inhibitor, with a LD 50 of 1.7 μM for cell population in AML cells. Has potential anti-cancer and anti-metastatic effectIn VitroDMAPT treatment decreased

DMAPT (Dimethylamino Parthenolide), an analogue of Parthenolide (PTL), is an oral active NF-κB inhibitor, with a LD 50 of 1.7 μM for cell population in AML cells. Has potential anti-cancer and anti-metastatic effectIn VitroDMAPT treatment decreased

DMAPT (Dimethylamino Parthenolide), an analogue of Parthenolide (PTL), is an oral active NF-κB inhibitor, with a LD 50 of 1.7 μM for cell population in AML cells. Has potential anti-cancer and anti-metastatic effectIn VitroDMAPT treatment decreased

DMP 777 is a potent, selective, and orally active human leukocyte elastase (HLE) inhibitor.In VivoDMP-777-treated rats show a marked decrease in H/K-ATPase staining parietal cells. DMP-777-induced loss of parietal cells is significantly ameliorated

DMP 777 is a potent, selective, and orally active human leukocyte elastase (HLE) inhibitor.In VivoDMP-777-treated rats show a marked decrease in H/K-ATPase staining parietal cells. DMP-777-induced loss of parietal cells is significantly ameliorated

DMP 777 is a potent, selective, and orally active human leukocyte elastase (HLE) inhibitor.In VivoDMP-777-treated rats show a marked decrease in H/K-ATPase staining parietal cells. DMP-777-induced loss of parietal cells is significantly ameliorated

DMP 777 is a potent, selective, and orally active human leukocyte elastase (HLE) inhibitor.In VivoDMP-777-treated rats show a marked decrease in H/K-ATPase staining parietal cells. DMP-777-induced loss of parietal cells is significantly ameliorated